ArticleCardio-oncology (London, England)2025

Rationale and design of the HOVON 170 DLBCL-ANTICIPATE trial: preventing anthracycline-induced cardiac dysfunction with dexrazoxane.

Marijke Linschoten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.